GlobeNewswire Inc.··Not SpecifiedKymera Therapeutics Advances IBD Pipeline With Promising KT-579 Preclinical Data
Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.
KYMRclinical trialinflammatory bowel disease